Kigabeq

Vigabatrin, the active ingredient in Kigabeq, is an Anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, complex partial seizures, and other forms of epilepsy in patients requiring additional seizure control and is used under medical supervision.

GNH USA supplies Kigabeq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Kigabeq (vigabatrin) is employed in the management of seizure disorders that involve abnormal neuronal firing.

- Partial seizures: reduces frequency and severity of focal seizures. - Complex partial seizures: helps control seizures arising from deeper brain structures. - Epilepsy: provides adjunctive therapy for patients with refractory epilepsy.

Vigabatrin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of excessive sleepiness. - Dizziness: sensation of light‑headedness or imbalance. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Vision loss: irreversible peripheral visual field constriction. - Depression: new or worsening depressive symptoms. - Seizure worsening: increase in seizure frequency. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing or dispensing Kigabeq, several safety considerations should be observed.

- Visual monitoring: conduct baseline and periodic visual field testing. - Renal function: assess kidney function before initiation and during therapy. - Discontinuation: avoid abrupt cessation; taper under medical guidance. - Mood assessment: monitor for signs of depression or suicidal thoughts. - Pregnancy: safety category unknown; weigh potential risks and benefits. - Store at room temperature: keep in original packaging, protect from moisture.

Vigabatrin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other GABAergic agents: may increase central nervous system depression. - Valproic acid: can raise vigabatrin plasma levels, enhancing toxicity risk. - Carbamazepine: may reduce vigabatrin effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives: efficacy may be decreased, consider alternative methods. - Antidepressants: monitor mood changes as combined effect on CNS. - Antacids: may affect absorption; separate dosing times.